AuroLase Therapy
Localized, low- to intermediate-risk Prostate Cancer
Phase 3Active
Key Facts
Indication
Localized, low- to intermediate-risk Prostate Cancer
Phase
Phase 3
Status
Active
Company
About Nanospectra Biosciences
Nanospectra Biosciences is a clinical-stage medical device company developing a novel, focal therapy for cancer using its proprietary AuroLase platform. The technology combines inert gold-silica nanoparticles with a near-infrared laser to achieve precise, incision-free thermal ablation of solid tumors, starting with prostate cancer. This approach aims to offer a targeted treatment with the potential to preserve organ function and reduce side effects compared to standard therapies. The company is advancing its lead program through pivotal clinical studies in the U.S. and has secured Breakthrough Device Designation from the FDA.
View full company profile